Inrig Jula: insider trades.
Inrig Jula reported 5 non-derivative transactions on 1 SEC ownership filings in Q3 2026: 0 open-market purchases and 4 sales ($2.8M), across 1 company.
- Transactions
- 5
- Purchases (P)
- 0
- Sales (S)
- 4
- Companies
- 1
- Name as filed
- Inrig Jula
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | Officer · EVP, Head of R&D & CMO | 5 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-15 | Travere Therapeutics, Inc. | M | 32,395 | $8.93 | 145,165 | Form 4 |
| 2026-09-15 | Travere Therapeutics, Inc. | S | 25,390 | $62.02 | 119,775 | Form 4 |
| 2026-09-15 | Travere Therapeutics, Inc. | S | 400 | $65.31 | 100,491 | Form 4 |
| 2026-09-15 | Travere Therapeutics, Inc. | S | 1,600 | $63.69 | 100,891 | Form 4 |
| 2026-09-15 | Travere Therapeutics, Inc. | S | 17,284 | $62.62 | 102,491 | Form 4 |
Questions
What stock did Inrig Jula buy or sell?
Inrig Jula reported 5 non-derivative transactions on 1 SEC ownership filings in Q3 2026: 0 open-market purchases and 4 sales ($2.8M), across 1 company.
Is Inrig Jula the same person as other filers with this name?
This page covers SEC CIK 1902368 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/inrig-jula-1902368.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.